SCHEMBL2404803

SCHEMBL2404803

COc1ccc(-c2ccc(O)c(C34CC5CC(CC(C5)C3)C4)c2)cc1/C=C/C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 7/20 0.67
PTPN11 Q06124 5/20 0.57
NR0B2 Q15466 3/20 0.57
RARA P10276 5/20 0.55
RARG P13631 5/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
NR1I2 O75469 1/20 0.55
LMNA P02545 1/20 0.55
PGR P06401 1/20 0.55
HSPD1 P10809 1/20 0.55
GOT1 P17174 1/20 0.55
GLRA1 P23415 1/20 0.55
BLM P54132 1/20 0.55
HSPE1 P61604 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
HDAC11 Q96DB2 5/20 0.55
HDAC2 Q92769 2/20 0.55
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404808 1.00 RARB (0.67) RARBPTPN11NR0B2RARARARG
SCHEMBL2394186 0.87 RARB (0.51) RARBPTPN11NR0B2RARARARG
SCHEMBL6620830 0.85 RARB (0.55) RARBPTPN11NR0B2RARARARG
SCHEMBL2394188 0.85 RARB (0.57) RARBPTPN11NR0B2RARARARG
SCHEMBL2402707 0.85 PTPN11 (0.70) RARBPTPN11NR0B2RARARARG
SCHEMBL2402695 0.85 PTPN11 (0.70) RARBPTPN11NR0B2RARARARG
SCHEMBL2403481 0.84 RARB (0.69) RARBPTPN11NR0B2RARARARG
SCHEMBL2403489 0.84 RARB (0.69) RARBPTPN11NR0B2RARARARG
SCHEMBL2404476 0.84 RARB (0.71) RARBPTPN11NR0B2RARARARG
SCHEMBL2404470 0.84 RARB (0.71) RARBPTPN11NR0B2RARARARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE42700-E1 Induction of apoptosis in cancer cells SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2011-09-13 US disclosed
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 US disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 RARB 577/4885PTPN11 2842/4885NR0B2 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.